Metabolism - Clinical and Experimental
Volume 52, Issue 12 , Pages 1576-1578 , December 2003

Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes

  • Ana Marı́a Wägner

      Affiliations

    • Department of Endocrinology, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Oscar Jorba

      Affiliations

    • Department of Endocrinology, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Mercedes Rigla

      Affiliations

    • Department of Endocrinology, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Rosa Bonet

      Affiliations

    • Department of Biochemistry, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Alberto de Leiva

      Affiliations

    • Department of Endocrinology, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Jordi Ordóñez-Llanos

      Affiliations

    • Department of Biochemistry, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
    • Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain
    • ,
  • Antonio Pérez

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Antonio Pérez, MD, PhD, Endocrinology and Nutrition Department, Hospital de Sant Pau, S Antonio M Claret 167, 08025 Barcelona, Spain
    • Department of Endocrinology, Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

Received 13 February 2003 ,Accepted 9 June 2003.

References 

  1. Syvänne M, Taskinen M. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet. 1997;350(suppl 1):20–23
  2. Wägner AM, Pérez A, Calvo F, et al.  Apolipoprotein B identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care. 1999;22:812–817
  3. Austin MA, Breslow JL, Hennekens CH, et al.  Low density lipoprotein subclass pattern and risk of myocardial infarction. JAMA. 1988;260:1917–1921
  4. Caixàs A, Ordóñez-Llanos J, de Leiva A, et al.  Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 1997;46:1207–1213
  5. Vakkilainen J, Steiner G, Ansquer JC, et al.  Relationship between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. Circulation. 2003;107:1733–1737
  6. Wolffenbuttel BHR, Sels JP, Rondas-Colbers GJ, et al.  Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care. 1996;19:1326–1332
  7. Caixàs A, Pérez A, Ordóñez-Llanos J, et al.  Lack of change of lipoprotein(a) levels by the optimization of glycemic control with insulin therapy in NIDDM patients. Diabetes Care. 1997;20:1459–1461
  8. Markovic TP, Campbell LV, Balasubramanian S, et al.  Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care. 1998;21:695–700
  9. Rivellese A, Patti L, Romano G, et al.  Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. J Clin Endocrinol Metab. 2000;85:4188–4192
  10. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  11. Marcovina SM, Albers JJ, Kennedy H, et al.  International Federation of Clinical Chemistry standardization project for measurement of apolipoproteins A-I and B. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994;40:586–592
  12. Nichols AV, Krauss RM, Musliner TA. Nondenaturating polyacrylamide gradient gel electrophoresis. In:  Segrest JP,  Albers LL editor. Methods in Enzymology (Plasma Lipoproteins). New York, NY: Academy Press; 1986;p. 417–431
  13. Wägner AM, Jorba O, Rigla M, et al.  LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol. 2002;39:215–220
  14. Pérez A, Wägner AM, Carreras G, et al.  Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes (Effect of glycemic control). Arch Intern Med. 2000;160:2756–2762
  15. James RW, Pometta D. The distribution of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:246–252
  16. Barakat HA, Carpenter JW, McLendon VD, et al.  Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis. Diabetes. 1990;39:1527–1533
  17. Chu NV, Kong APS, Kim DD, et al.  Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542–549

PII: S0026-0495(03)00326-3

doi: 10.1016/S0026-0495(03)00326-3

Metabolism - Clinical and Experimental
Volume 52, Issue 12 , Pages 1576-1578 , December 2003

Article Tools